Anixa Biosciences Inc

Anixa Biosciences Inc

Anixa Biosciences Inc began as a technology consulting firm in 1983 before pivoting to biotechnology in the 2010s. CEO Amit Kumar has led the transformation, repositioning the company toward cancer treatment development. The underlying wealth stems from public market financings rather than a single family fortune. The firm's strategy centers on immunotherapies and vaccines for cancers with high unmet need. Its lead asset, a vaccine targeting triple-negative breast cancer, is being developed in collaboration with the Cleveland Clinic (per the firm, 2023). A second program targets ovarian cancer. Anixa uses a lean R&D model, outsourcing manufacturing and relying on academic partnerships for clinical work. The company also holds a portfolio of IT patents from its earlier era, generating modest licensing revenue. Anixa is a publicly traded company, not a family office. As of 2025, the firm had approximately 20 employees and no disclosed AUM. The company raised capital through public offerings and grants, most recently a $10 million registered direct offering in March 2024 (per SEC filing, 2024). There are no known philanthropic arms or ancillary vehicles. The firm's structural differentiator lies in its focused, capital-efficient approach to oncology vaccine development — outsourcing most non-core functions while retaining intellectual property. This contrasts with larger biotechs that maintain in-house manufacturing and broad pipelines. Anixa's relationship with the Cleveland Clinic provides academic validation and clinical infrastructure without the overhead of a corporate research lab.